Skip to main content
Caplight Logo









Veradermics Inc.

Veradermics Inc.

Public

Veradermics Inc. is now publicly traded

The data on this page reflects Veradermics Inc.'s private-market history up to the point it went public, including its funding rounds, valuation, and investors.

Went Public

Feb 3, 2026

Last Round

Follow-on Offering

May 1, 2026

Total Funding Raised

$585.5M

Company Overview

The recorded funding history for Veradermics Inc. includes a Series C round in October 2025. Veradermics Inc. has raised $585.5M.

Veradermics Inc. is a biopharmaceutical company that develops first-in-class therapeutics for dermatologic and aesthetic conditions, including pattern hair loss, common warts, and molluscum contagiosum.

AI Layer

Non-AI

Veradermics Inc. Comparables

Compare Veradermics Inc. with similar companies based on industry and business-model similarity.

No comparables are published for Veradermics Inc.. Book a demo to ask about coverage.

Book a demo

For institutional investors. Book with your work email.

Veradermics Inc. Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Follow-on OfferingMay 1, 2026
IPOFeb 3, 2026
Series COct 16, 2025
Series BDec 11, 2024
Private PlacementApr 25, 2023
Series A
Sep 22, 2021
Book a demo to see all funding rounds

For institutional investors. Book with your work email.

Key People

Founding team and executive leadership

Reid Waldman

Chief Executive Officer, Founder

Founding Team

Dominic Carrano

Chief Financial Officer

Executive Team

For institutional investors. Book with your work email.

Veradermics Inc. Investors

Notable investors and investment history

Veradermics Inc. investors
InvestorRounds
JefferiesIPO
Longitude CapitalSeries B, Series C
Surveyor CapitalSeries C
Connecticut InnovationsSeries B, Series A
LifeSci Venture PartnersSeries C
abrdn Inc.Series C
Columbia Threadneedle InvestmentsSeries C
Book a demo to see all 20 investors

For institutional investors. Book with your work email.

Recent news

Latest coverage and updates

  • has_lossNov 10, 2026

    Veradermics reports a $21M net loss in Q3 '26, up $0.9 million from $20.1 million a year earlier.

Book a demo to see all news

For institutional investors. Book with your work email.

Veradermics Inc. Filings

Explore SEC and related filing metadata, where available.

Veradermics Inc. filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Book a demo

For institutional investors. Book with your work email.

Firmographic Details

Headquarters—
Employee Range38
Year Founded2019
Last FundingMay 1, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Book a demo

For institutional investors. Book with your work email.

See something wrong or outdated?